Cengild poised for further robust growth post IPO. ------------------------------------------------- Cengild raised RM72 million from its IPO with 218.8 million new shares.
Of the proceeds, it intends to use RM37.1 million to establish new medical centres, RM17.4 million for working capital, RM13 million for expansion of existing medical centres and the remaining RM4.7 million for listing expenses.
The group plans to expand its existing medical centre at Nexus @ Bangsar South, Kuala Lumpur, by leasing additional space of approximately 12,000 to 15,000 square feet to cater to current and future demand for its medical services, especially endoscopic procedures to strengthen its position in the segment.
It also intends to expand its presence by establishing two new full-fledged medical centres specialising in gastrointestinal and liver diseases, and obesity in other major cities in Malaysia such as Johor Bahru, Penang or Ipoh.
In order to support the expansion of its existing medical centre as well as into other major cities in Malaysia, it also intends to strengthen its medical team by attracting and recruiting consultants specialising in gastroenterology and hepatology.
Cengild has travelled through a remarkable journey since October 2017 and this IPO has provided us with the platform to realize our ambitions and accelerate our expansion plans.
"As the only independent full-fledged medical centre in Malaysia specialising in gastrointestinal and liver diseases, and obesity, our aim is not only to provide the best treatment for our patients, but also to build a reputable centre of excellence in the region," said Cengild Medical executive chairman Datuk Tan Huck Joo in a statement.
I think there are a possibility to goreng healthcare stock sooner or later, as market we can see there are few listed co is actually potential. Cengild, scomnet, optimax is actually not bad. Can keep monitor and look for a good price to enter
Cenglid to venture into Urology & Cardiology via JV's. ----------------------------------------------------- 1-UNCKL Sdn Bhd (UNCKL) is a 30%-owned subsidiary of Cengild that is formed to offer urology services to Cengild. Presently, UNCKL is dormant for the execution of its shareholders agreement and things are still pending between KL Urology (UNCKL’s other shareholder who owns its balance 70% shareholdings) and Cengild.
2-Cengild and Dr. Hendrick Chia had formed a joint venture (JV) company namely, Cardiac Care Centre Sdn Bhd (CCC), where Cengild owns 30% shareholdings and Dr. Hendrick holds the other 70% shareholdings of the JV company. Presently, it provides cardiology assessments to patients at Cengild’s medical centre.
Besides the main 6 consultants, Cengild also have : Visiting consultants=17
One of the 6 consultants, Dato' Dr Tan Huck Joo is also a visiting consultant for Sunway Medical Centre, C-G-3, Ground Floor, Tower C, +603-7491 9191 (Ext. 20527)
Thus, the visiting consultants can cover the operations even if 1-2 of the main consultants decided to leave. Of course, leaving without their ESOS.
Cengild poised for further robust growth post IPO. ------------------------------------------------- Cengild raised RM72 million from its IPO with 218.8 million new shares.
Of the proceeds, it intends to use RM37.1 million to establish new medical centres, RM17.4 million for working capital, RM13 million for expansion of existing medical centres and the remaining RM4.7 million for listing expenses.
The group plans to expand its existing medical centre at Nexus @ Bangsar South, Kuala Lumpur, by leasing additional space of approximately 12,000 to 15,000 square feet to cater to current and future demand for its medical services, especially endoscopic procedures to strengthen its position in the segment.
It also intends to expand its presence by establishing two new full-fledged medical centres specialising in gastrointestinal and liver diseases, and obesity in other major cities in Malaysia such as Johor Bahru, Penang or Ipoh.
In order to support the expansion of its existing medical centre as well as into other major cities in Malaysia, it also intends to strengthen its medical team by attracting and recruiting consultants specialising in gastroenterology and hepatology.
Cengild poised for further robust growth post IPO. ------------------------------------------------- Cengild raised RM72 million from its IPO with 218.8 million new shares.
Of the proceeds, it intends to use RM37.1 million to establish new medical centres, RM17.4 million for working capital, RM13 million for expansion of existing medical centres and the remaining RM4.7 million for listing expenses.
The group plans to expand its existing medical centre at Nexus @ Bangsar South, Kuala Lumpur, by leasing additional space of approximately 12,000 to 15,000 square feet to cater to current and future demand for its medical services, especially endoscopic procedures to strengthen its position in the segment.
It also intends to expand its presence by establishing two new full-fledged medical centres specialising in gastrointestinal and liver diseases, and obesity in other major cities in Malaysia such as Johor Bahru, Penang or Ipoh.
In order to support the expansion of its existing medical centre as well as into other major cities in Malaysia, it also intends to strengthen its medical team by attracting and recruiting consultants specialising in gastroenterology and hepatology.
Cengild poised for further robust growth post IPO. ------------------------------------------------- Cengild raised RM72 million from its IPO with 218.8 million new shares.
Of the proceeds, it intends to use RM37.1 million to establish new medical centres, RM17.4 million for working capital, RM13 million for expansion of existing medical centres and the remaining RM4.7 million for listing expenses.
The group plans to expand its existing medical centre at Nexus @ Bangsar South, Kuala Lumpur, by leasing additional space of approximately 12,000 to 15,000 square feet to cater to current and future demand for its medical services, especially endoscopic procedures to strengthen its position in the segment.
It also intends to expand its presence by establishing two new full-fledged medical centres specialising in gastrointestinal and liver diseases, and obesity in other major cities in Malaysia such as Johor Bahru, Penang or Ipoh.
In order to support the expansion of its existing medical centre as well as into other major cities in Malaysia, it also intends to strengthen its medical team by attracting and recruiting consultants specialising in gastroenterology and hepatology.
New IPO: A homegrown air fragrance company, Vanzo Holdings Berhad aims to list on the Ace Market!
MQ Trader 74 views | 8 h ago
0:17
New IPO: Winstar Capital Berhad, a specialist in the extrusion of aluminium profiles and fabrication of aluminium ladders aims to list on the ACE Market!
MQ Trader 268 views | 1 d ago
0:17
New IPO: Topvision Eye Specialist Berhad, specializing in medical eye care services aims to list on the ACE Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
BE_GREEEEEDY
1,834 posts
Posted by BE_GREEEEEDY > 2022-04-18 10:52 | Report Abuse
COMINGGGG again.
ATTACCKKKKKKKKKKK $$$$